Navigation Links
Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
Date:1/7/2008

evelopment of drugs for the treatment of human viral and other infectious diseases. Idenix's current focus is on the treatment of infections caused by hepatitis C virus and HIV. For further information about Idenix, please refer to http://www.idenix.com.

Forward-looking Statements

This press release contains "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward- looking statements can be identified by the use of forward-looking terminology such as "could," "may," "plans," "will," or similar expressions, or by express or implied statements with respect to the company's clinical development programs in hepatitis C, or any potential pipeline candidates for the treatment of hepatitis C. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantees that the company will advance any clinical product candidate or other component of its potential pipeline to the clinic, to the regulatory process or to commercialization. In particular, management's expectations could be affected by unexpected regulatory actions or delays; uncertainties relating to, or unsuccessful results of, pre-clinical studies and/or clinical trials, including additional data relating to the ongoing pre-clinical studies and/or clinical trials evaluating its product candidates; the company's ability to obtain additional funding required to conduct its research, development and commercialization activities; the company's dependence on its collaboration with Novartis Pharma AG; changes in the company's business plan or objectives; the ability of the company to attract and retain qualified personnel; competition in general; and the company's ability to obtain, maintain and e
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
4. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
5. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
6. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
7. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
8. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
9. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
10. Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting
11. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Stem Cell Transplantation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013  Omeros Corporation ... its Investigational New Drug Application (IND) to evaluate ... the U.S. Food and Drug Administration (FDA). OMS824 ... in areas of the brain linked to a ... Huntington,s disease and schizophrenia. OMS824 has shown promising ...
(Date:5/23/2013)... YORK , May 23, 2013  Echo Pharma ... committed to waive down the Acceptance Threshold from 90 ... plus one Elan Share in accordance with the terms ... the conditions summarized below. Under the terms ... acquire Elan (NYSE: ELN ) for $12.50 ...
(Date:5/23/2013)... CHERTSEY , Engeland, May 23, 2013 ... goed voor mannen met lagere urinewegsymptomen geassocieerd met BPH ... BV, de Europese dochteronderneming van Astellas Pharma Inc, gebaseerd ... : 4503), kondigde vandaag aan dat het Nederlandse ... verleend voor VESOMNI in Nederland. De handelsvergunning ...
Breaking Medicine Technology:Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 3Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 4Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 2Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 3Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 4Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 5Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 6Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 7Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 8Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 9Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 10Astellas ontvangt handelsvergunning voor VESOMNITM van Nederlandse College ter Beoordeling van Geneesmiddelen 2Astellas ontvangt handelsvergunning voor VESOMNITM van Nederlandse College ter Beoordeling van Geneesmiddelen 3Astellas ontvangt handelsvergunning voor VESOMNITM van Nederlandse College ter Beoordeling van Geneesmiddelen 4
... /PRNewswire-Asia/ -- Chindex International, Inc. ("Chindex") (Nasdaq: ... healthcare products and services in the People,s Republic of ... financial results for the three and nine-month periods ended ... the market closes. Management will host a conference call ...
... March 4, 2011 A group of Canadian researchers led ... Osteoarthritis Research Unit at the University of ... trial in which they confirm, for the ... (qMRI), the disease modifying effects of chondroitin sulphate, a symptomatic ...
Cached Medicine Technology:Chindex International to Report Financial Results for the Three and Nine-Month Periods Ended December 31, 2010 2The Disease Modifying Effect of Chondroitin Sulphate in Patients With Knee Osteoarthritis Has Been Confirmed by MRI 2The Disease Modifying Effect of Chondroitin Sulphate in Patients With Knee Osteoarthritis Has Been Confirmed by MRI 3
(Date:5/23/2013)... Steven Reinberg HealthDay Reporter , , THURSDAY, May ... heartburn may be at increased risk for cancers of ... smoke or drink alcohol, a new study says. ... cancers while prescription medications such as Prilosec, Nexium and ... a controversy about whether heartburn contributes to cancers of ...
(Date:5/23/2013)... of older adults with dementia are less stressed ... dementia patients receive adult day services (ADS), according ... with and care for someone with dementia can ... professor and head, human development and family studies. ... provide caregivers with a much-needed break that can ...
(Date:5/23/2013)... YORK (May 23, 2013) -- Little is known about ... why response to treatments varies between patients. Now, a ... University Medical Center and SUNY Downstate Medical Center has ... asthma, showing that it is very different from other ... Medicine , reveals that an over-active gene linked in ...
(Date:5/23/2013)... researchers at Henry Ford Hospital found "substantial evidence" that ... spinal cord could hold the key to better functional ... new hope to those who suffer stroke, the leading ... victims recover some ability to voluntarily use their hands ... weakness on one side of their bodies, while a ...
(Date:5/23/2013)... It is Go Classy Tours / Caribbean Hideaways' ... Spa , a luxury nudist resort located in the Rivera ... International Naked Painting Party. Hidden Beach is a perfect location ... Hot Tub, Nude Bars & Nightclub and Nude Dinning. ... August 15th and go through August 18th, with the actual ...
Breaking Medicine News(10 mins):Health News:Chronic Heartburn May Raise Odds for Throat Cancer: Study 2Health News:Adult day services for dementia patients provide stress relief to family caregivers 2Health News:Researchers find common childhood asthma unconnected to allergens or inflammation 2Health News:Researchers find common childhood asthma unconnected to allergens or inflammation 3Health News:Regenerating spinal cord fibers may be treatment for stroke-related disabilities 2Health News:Regenerating spinal cord fibers may be treatment for stroke-related disabilities 3Health News:Hidden Beach, the Only Luxurious All-inclusive Nudist Resort in the Mexican Caribbean, to Host Social Exposure's Naked Painting Party, Announces Go Classy Tours 2
... INDIANAPOLIS, June 22 The board of directors of Eli Lilly and ... third quarter of 2009 of $0.49 a share on outstanding common stock. ... and second quarters and maintains the annual indicated dividend rate for 2009 ... September 10, 2009, to shareholders of record at the close of business ...
... blames physician misdiagnosis as the likely cause of apparent uptick ... A newly released study in the June 2009 British Journal ... the eastern United Kingdom has concluded that the much-hyped melanoma ... The study attributed the increase in melanoma diagnoses to heightened ...
... MIAMI, June 22 Now there,s a new ... time, suggests a new,study published in the July issue of ... drinking fat free milk in the,morning helped increase satiety, or ... the next meal, as compared with a fruit drink. The,milk ...
... , , , Personalized Medicine Meeting ... The Food and Drug Administration,s (FDA,s) ability to regulate genetic ... medicine stakeholders. , , Three-quarters of the attendees ... and Drug Law Institute (FDLI) and the American Association for ...
... NIH declines to attend field hearing exploring use of Recovery ... U.S. Senator Benjamin L. Cardin (D-MD ), chaired a ... Business and Entrepreneurship in Rockville, MD, entitled " Missed ... the hearing, local and national experts in biotechnology testified about ...
... Courage Center,s two camps, Camp Courage in Maple Lake ... camp schedule for people with disabilities. , , A recent ... participants (campers and MDA staff) who tested positive for H1N1 flu ... 6-12. Courage Center officials were contacted by the MDA locally three ...
Cached Medicine News:Health News:New Study Says Purported Melanoma Epidemic is Vastly Overstated 2Health News:Drinking Milk in the Morning May Help Stave off Lunchtime Hunger 2Health News:FDA's Current Ability to Regulate Genetic Testing is Problematic, FDLI-AAAS Colloquium Attendees Say 2Health News:FDA's Current Ability to Regulate Genetic Testing is Problematic, FDLI-AAAS Colloquium Attendees Say 3Health News:Cardin Calls on NIH to Utilize Small Businesses for Extramural Research Projects 2Health News:Courage Camps Maintain Summer Camp Schedule for Children and Adults With Disabilities 2
15" Monopolar Electrode, Ins., Hook Tip...
... versatile, dependable 990 frame the ... and completes the Nova diagnostic ... stands out due to its ... and its integral safety cut ...
... is an innovative and efficient inverted ... complements any research facility. Improved mechanics ... offers the TS100 binocular and TS100-F ... comes with a photo port that ...
... monochrome IR/DIC video camera. Olympus wide array of ... image quality and flexibility you need for an ... high-resolution, real-time image of your specimen that can ... TV. You can even record movies when these ...
Medicine Products: